Comparison of maternal and fetal blood levels of caffeine and its metabolite. A pilot study by Wierzejska, Regina et al.
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e Nr 7/2014500
P R A C E  O R Y G I N A L N E
    
  położnictwo
Ginekol Pol. 2014, 85, 500-503
Comparison of maternal and fetal blood levels 
of caﬀeine and its metabolite. A pilot study








1 Department of Nutrition and Dietetics with Clinic of Metabolic Diseases and Gastroenterology, National Food and Nutrition Institute, Warsaw, Poland
2 Clinic of Obstetrics, Gynecology and Oncology, 2nd Faculty of Medicine, Medical University of Warsaw, Poland
 Abstract      
Objective: The aim of the study was to compare caﬀeine and paraxanthine concentrations in venous blood of 
pregnant women and in the umbilical cord blood of their newborns.
Materials and Methods: Pregnant women who gave birth at the Clinic of Obstetrics, Gynecology and Oncology, 
2nd Faculty of Medicine, Medical University of Warsaw were included in the study. Caﬀeine and paraxanthine con-
centrations were analyzed in 30 samples of venous blood serum drawn from the women before delivery and 30 
samples of umbilical cord blood serum of their newborns. Caﬀeine intake in the last 24 hours before delivery was  
estimated using a questionnaire. Statistical analysis employed a linear logistic regression model, Wilcoxon rank sum 
test and a non-parametric Spearman’s rank correlation coeﬃcient.
Results: No diﬀerence was found between caﬀeine concentration in maternal venous blood and neonatal umbilical 
cord blood. However, paraxanthine level in venous blood was higher than in umbilical cord blood (p = 0.04). 
Conclusions: Caﬀeine consumed by a pregnant woman passes through the placenta to the fetus freely.
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 Streszczenie
Cel: Porównanie stężenia kofeiny i jej metabolitu (paraksantyny) we krwi żylnej kobiet ciężarnych i krwi pępowino-
wej noworodków.
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Materiał i metody: W badaniu wzięło udział 30 pacjentek rodzących w Klinice Położnictwa, Chorób Kobiecych 
i Ginekologii Onkologicznej II Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego (analizie poddano 
30 zestawów krwi „matka-dziecko”). Spożycie kofeiny przez kobiety ciężarne zostało oszacowane za pomocą 
wywiadu o spożyciu z ostatnich 24 godzin. W analizie statystycznej wykorzystano wieloczynnikowy model regresji 
logitowej, korelację liniową Spearmana, test sumy rangowych znaków Wilcoxona.
Wyniki: Nie stwierdzono różnicy w stężeniu kofeiny pomiędzy krwią żylną kobiet i pępowinową noworodków, nato-
miast stężenie paraksantyny we krwi matek było większe niż we krwi noworodków (p = 0,04). 






Table I. Characteristics of the pregnant women (Charakterystyka kobiet ciężarnych).
N=30 Range
Maternal age [years] 19 – 38
Caffeine intake in the last 24 hours [mg] 0 – 224
Caffeine concentration in venous blood 
[μg/ml] 0.02 –6.4
Caffeine concentration in umbilical cord 
blood [μg/ml] 0.05 – 7.22
Paraxanthine concentration in venous 
blood [μg/ml] 0.01 – 1.45
Paraxanthine concentration in umbilical 
cord blood [μg/ml] 0.01 – 1.19
Number of women smoking during 
pregnancy 6
Pregnancy length [weeks] 37 – 42
Neonatal body weight [g] 2550 – 4466
Apgar score 9-10
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Figure 1. Average caﬀeine and paraxanthine concentration in blood.
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